1.How to Improve Influenza Vaccination Rates in the U.S..
Journal of Preventive Medicine and Public Health 2011;44(4):141-148
Annual epidemics of seasonal influenza occur during autumn and winter in temperate regions and have imposed substantial public health and economic burdens. At the global level, these epidemics cause about 3-5 million severe cases of illness and about 0.25-0.5 million deaths each year. Although annual vaccination is the most effective way to prevent the disease and its severe outcomes, influenza vaccination coverage rates have been at suboptimal levels in many countries. For instance, the coverage rates among the elderly in 20 developed nations in 2008 ranged from 21% to 78% (median 65%). In the U.S., influenza vaccination levels among elderly population appeared to reach a "plateau" of about 70% after the late 1990s, and levels among child populations have remained at less than 50%. In addition, disparities in the coverage rates across subpopulations within a country present another important public health issue. New approaches are needed for countries striving both to improve their overall coverage rates and to eliminate disparities. This review article aims to describe a broad conceptual framework of vaccination, and to illustrate four potential determinants of influenza vaccination based on empirical analyses of U.S. nationally representative populations. These determinants include the ongoing influenza epidemic level, mass media reporting on influenza-related topics, reimbursement rate for providers to administer influenza vaccination, and vaccine supply. It additionally proposes specific policy implications, derived from these empirical analyses, to improve the influenza vaccination coverage rate and associated disparities in the U.S., which could be generalizable to other countries.
Health Status Disparities
;
Humans
;
Influenza Vaccines/*administration & dosage
;
Influenza, Human/epidemiology/*prevention & control
;
Patient Acceptance of Health Care
;
United States/epidemiology
;
Vaccination/*trends/utilization
2.Implication of reported viral hepatitis incidence rate change in Hubei Province, China, between 2004-2010.
Ying HU ; Chuanhua YU ; Banghua CHEN ; Lei WANG
Journal of Huazhong University of Science and Technology (Medical Sciences) 2012;32(3):428-433
This study examined the change of reported incidence rate for viral hepatitis in Hubei province, China, between 2004 to 2010 to provide scientific evidence for viral hepatitis control. Reported viral hepatitis infection cases were queried from Centre for Disease Control of Hubei Province, China. The incidence of viral hepatitis A decreased steadily across the study period. Viral hepatitis B composed 85% of the viral hepatitis cases. When reported incidence rates for chronic hepatitis B increased, the rates of acute and unclassified cases dropped from 2005 to 2010. The reported viral hepatitis B incidence rate for males was around 1.5-2 times higher than for females. The average annual percentage change of reported viral hepatitis B incidence rates was 4%. The same index for viral hepatitis C was 28%. The reported viral hepatitis B incidence rate of people under 20 years old declined over the period. This decrease was mainly attributed to the recent implementation of vaccination plan. Reported incidence rate of viral hepatitis E also rose in those years. Having a better understanding on reported incidence rates of the present surveillance system is important for developing strategies for further prevention of viral hepatitis. In addition, the data showed that a surveillance system that differentiates new and former infected cases will be more effective in providing evidence for disease control.
Adolescent
;
Adult
;
Age Distribution
;
Aged
;
Aged, 80 and over
;
Child
;
Child, Preschool
;
China
;
epidemiology
;
Female
;
Hepatitis, Viral, Human
;
epidemiology
;
prevention & control
;
Humans
;
Incidence
;
Infant
;
Infant, Newborn
;
Male
;
Mass Vaccination
;
trends
;
utilization
;
Middle Aged
;
Risk Factors
;
Sex Distribution
;
Viral Hepatitis Vaccines
;
therapeutic use
;
Young Adult